Foster & Motley Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 39.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,394 shares of the company’s stock after buying an additional 15,200 shares during the period. Johnson & Johnson comprises approximately 1.2% of Foster & Motley Inc.’s holdings, making the stock its 28th largest position. Foster & Motley Inc.’s holdings in Johnson & Johnson were worth $6,307,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in JNJ. Emerald Acquisition Ltd. acquired a new position in shares of Johnson & Johnson during the second quarter worth about $805,455,000. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the period. BlackRock Fund Advisors increased its position in shares of Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the period. Capital World Investors increased its position in shares of Johnson & Johnson by 10.3% in the second quarter. Capital World Investors now owns 22,025,323 shares of the company’s stock worth $2,671,672,000 after buying an additional 2,050,323 shares during the period. Finally, Capital International Investors acquired a new position in shares of Johnson & Johnson during the second quarter worth about $227,704,000. 64.05% of the stock is owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) traded down 1.155% during mid-day trading on Wednesday, hitting $114.818. The company had a trading volume of 3,560,142 shares. The company has a market cap of $312.37 billion, a PE ratio of 20.154 and a beta of 0.72. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company’s 50 day moving average price is $114.36 and its 200-day moving average price is $118.35.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.66 by $0.02. The business had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted $1.49 EPS. Equities research analysts anticipate that Johnson & Johnson will post $6.71 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 14th. Investors of record on Tuesday, February 28th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Friday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.64%.
COPYRIGHT VIOLATION NOTICE: “Foster & Motley Inc. Boosts Position in Johnson & Johnson (JNJ)” was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of US & international trademark and copyright law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/foster-motley-inc-boosts-position-in-johnson-johnson-jnj/344950.html.
A number of brokerages recently issued reports on JNJ. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $121.63 price target for the company in a report on Monday. Credit Suisse Group reiterated a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a research note on Monday, September 19th. RBC Capital Markets reiterated a “buy” rating and issued a $133.00 price objective on shares of Johnson & Johnson in a research note on Friday, January 6th. Finally, Jefferies Group reduced their price objective on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $122.22.
In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the business’s stock in a transaction on Friday, October 21st. The shares were purchased at an average price of $114.11 per share, with a total value of $99,846.25. Following the purchase, the director now directly owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.11% of the stock is owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.